Zhengye Biotechnology Holding Limited Ordinary Shares Total Assets
Zhengye Biotechnology Holding Limited Ordinary Shares total assets. Based on the latest financial reports, Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) holds total assets worth $493.25 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ZYBT market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Zhengye Biotechnology Holding Limited Ordinary Shares (2021–2025)
Total assets of Zhengye Biotechnology Holding Limited Ordinary Shares from 2021 to 2025. This chart illustrates how Zhengye Biotechnology Holding Limited Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See Zhengye Biotechnology Holding Limited Or share price for real-time trading data and today's change.
Zhengye Biotechnology Holding Limited Ordinary Shares - Asset Composition Analysis
Zhengye Biotechnology Holding Limited Ordinary Shares Total Assets Breakdown (December 2025)
Zhengye Biotechnology Holding Limited Ordinary Shares total assets breakdown as of December 2025. Zhengye Biotechnology Holding Limited Ordinary Shares's total assets of $493.25 Million consist of 36.0% current assets and 64.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.8% |
| Accounts Receivable | $88.52 Million | 18.0% |
| Inventory | $58.22 Million | 11.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $22.78 Million | 4.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Zhengye Biotechnology Holding Limited Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Zhengye Biotechnology Holding Limited Or short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhengye Biotechnology Holding Limited Ordinary Shares's current assets represent 36.0% of total assets in 2025, a decrease from 37.0% in 2021.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2025, up from 1.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 2.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 18.0% of total assets.
Zhengye Biotechnology Holding Limited Ordinary Shares Competitors by Total Assets
Key competitors of Zhengye Biotechnology Holding Limited Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Zhengye Biotechnology Holding Limited Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.31 | 1.38 | 1.41 |
| Quick Ratio | 0.88 | 0.91 | 1.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $41.66 Million | $52.31 Million | $62.08 Million |
Zhengye Biotechnology Holding Limited Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Zhengye Biotechnology Holding Limited Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.28 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $493.25 Million |
| Market Capitalization | $54.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhengye Biotechnology Holding Limited Ordinary Shares's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhengye Biotechnology Holding Limited Ordinary Shares's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhengye Biotechnology Holding Limited Ordinary Shares (2021–2025)
The table below shows the annual total assets of Zhengye Biotechnology Holding Limited Ordinary Shares from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $493.25 Million | 0.00% |
| 2024-12-31 | $493.25 Million | -1.33% |
| 2023-12-31 | $499.89 Million | -3.81% |
| 2022-12-31 | $519.67 Million | +16.71% |
| 2021-12-31 | $445.28 Million | -- |
About Zhengye Biotechnology Holding Limited Ordinary Shares
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for househol… Read more